文献速递肝病

随机临床试验:索磷布韦/雷迪帕韦治疗输血依赖型地中海贫血合并HCV基因1或4型感染

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.
PubMed 文献 · Aliment Pharmacol Ther · 2017-06-29

本研究为开放标签、历史对照、全国多中心研究,评估索磷布韦/雷迪帕韦固定剂量组合治疗12周(不含利巴韦林)对100例地中海贫血major合并HCV基因1或4型感染患者的疗效,其中16%有肝硬化。研究组持续病毒学应答率为98%(95%CI 95.3%-100%),肝硬化及既往治疗失败者均达100%;历史对照组(96例,接受聚乙二醇干扰素/利巴韦林)持续病毒学应答率为47.9%(95%CI 37.9%-57.9%)。研究组不良事件(乏力、头痛、恶心、血红蛋白下降或铁蛋白升高)罕见且显著少于对照组。

要点

  • 索磷布韦/雷迪帕韦治疗12周在输血依赖型地中海贫血合并HCV基因1或4型患者中持续病毒学应答率达98%。
  • 肝硬化及既往治疗失败亚组均达100%持续病毒学应答。
  • 不良事件罕见且显著少于聚乙二醇干扰素/利巴韦林历史对照组。

核心结论

  • 索磷布韦/雷迪帕韦治疗12周为HCV基因1或4型地中海贫血患者提供简单、高效且安全的无聚乙二醇干扰素/利巴韦林方案。

研究设计与样本

  • 开放标签、历史对照、全国多中心研究,纳入100例地中海贫血major合并HCV基因1或4型感染患者,其中16%有肝硬化;对照组为96例基线特征可比、接受聚乙二醇干扰素/利巴韦林治疗的患者。

主要发现

  • 研究组持续病毒学应答率为98%(95%CI 95.3%-100%),肝硬化及既往治疗失败者均达100%持续病毒学应答。
  • 对照组持续病毒学应答率为47.9%(95%CI 37.9%-57.9%)。
  • 不良事件包括乏力、头痛、恶心、血红蛋白下降或铁蛋白升高,在研究组罕见且显著少于历史对照组。

关键数值与推荐

  • 研究组:索磷布韦/雷迪帕韦单药片剂治疗12周,持续病毒学应答率98%(95%CI 95.3%-100%)。
  • 对照组:聚乙二醇干扰素/利巴韦林,持续病毒学应答率47.9%(95%CI 37.9%-57.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with thalassaemia major depend on blood transfusions. In Italy, up to 80% of thalassaemia patients bear HCV antibodies due to HCV contaminated transfusions before 1990. Thalassaemia patients with HCV infection have high risk of developing HCC. Treatment based on Pegylated-IFN (Peg-IFN) and Ribavirin (RBV) was limited by relevant side effects. AIM: To evaluate the impact of Sofosbuvir/Ledipasvir (SOF/LDV) fixed dose combination for 12 weeks without RBV, in patients with thalassaemia major and HCV Genotype 1 or 4 (GT1/4). METHODS: Open label, historically-controlled, nationwide multicentre study in thalassaemia patients including naïve with cirrhosis and prior treatment failure without cirrhosis. SOF/LDV single pill was administered for 12 weeks to 100 patients of whom 16% had cirrhosis. The control group included 96 patients with comparable baseline characteristics treated with Peg-IFN/RBV. The primary end point was sustained virologic response at follow-up week 12 or 24 after IFN-free or Peg-IFN/RBV, respectively. RESULTS: In the study group, sustained virological response (SVR) was reported in 98% of patients (95% CI 95.3%-100%). Cirrhotic as well as prior treatment failure achieved 100% SVR. In the control group, SVR was 47.9% (95% CI 37.9%-57.9%). Adverse events including fatigue, headache, nausea, decrease in haemoglobin or increase in ferritin levels were rare and significantly less common in the study than in the historical control group. CONCLUSIONS: In conclusion, SOF/LDV for 12 weeks provides simple, highly effective and safe Peg-IFN/RBV-free treatment for HCV GT1/4 thalassaemia patients. EUDRACT number 2015-002401-1.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mangia A, Sarli R, Gamberini R, et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther. 2017. PMID: 28660640. doi:10.1111/apt.14197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。